NOVELIXHealthcare Research, Analytics & Technology
NOVELIX PHARMACEUTICALS LIMITE — Balance Sheet
₹55.78
-3.48%
NOVELIX PHARMACEUTICALS LIMITE Balance Sheet (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Ordinary Shares Number | 0.99 Cr | 0.81 Cr | 0.81 Cr | 0.81 Cr | — |
| Share Issued | 0.99 Cr | 0.81 Cr | 0.81 Cr | 0.81 Cr | — |
| Total Debt | 0.00 | — | — | 0.16 Cr | 0.00 |
| Tangible Book Value | 17.54 Cr | 7.35 Cr | 7.20 Cr | 7.24 Cr | — |
| Invested Capital | 17.54 Cr | 7.35 Cr | 7.20 Cr | 7.24 Cr | — |
| Working Capital | 17.27 Cr | 4.12 Cr | 4.18 Cr | 4.62 Cr | — |
| Net Tangible Assets | 17.54 Cr | 7.35 Cr | 7.20 Cr | 7.24 Cr | — |
| Common Stock Equity | 17.54 Cr | 7.35 Cr | 7.20 Cr | 7.24 Cr | — |
| Total Capitalization | 17.54 Cr | 7.35 Cr | 7.20 Cr | 7.24 Cr | — |
| Total Equity Gross Minority Interest | 17.54 Cr | 7.35 Cr | 7.20 Cr | 7.24 Cr | — |
| Stockholders Equity | 17.54 Cr | 7.35 Cr | 7.20 Cr | 7.24 Cr | — |
| Other Equity Interest | 7.59 Cr | -0.75 Cr | — | 0.07 Cr | -1.24 Cr |
| Capital Stock | 9.95 Cr | 8.10 Cr | 8.10 Cr | 8.10 Cr | — |
| Common Stock | 9.95 Cr | 8.10 Cr | 8.10 Cr | 8.10 Cr | — |
| Total Liabilities Net Minority Interest | 9.67 Cr | 0.01 Cr | 0.06 Cr | 81500.00 | — |
| Total Non Current Liabilities Net Minority Interest | -1000.00 | 0.00 | 0.00 | 0.00 | — |
| Other Non Current Liabilities | -1000.00 | — | — | — | 1000.00 |
| Non Current Deferred Taxes Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Long Term Debt And Capital Lease Obligation | 0.00 | — | — | 0.13 Cr | 0.00 |
| Long Term Debt | 0.00 | — | — | 0.13 Cr | 0.00 |
| Current Liabilities | 9.67 Cr | 0.01 Cr | 0.06 Cr | 81500.00 | — |
| Other Current Liabilities | 1000.00 | 71320.00 | — | 0.01 Cr | 0.03 Cr |
| Current Debt And Capital Lease Obligation | 0.00 | — | — | 0.03 Cr | 0.00 |
| Current Debt | 0.00 | — | — | 0.03 Cr | 0.00 |
| Current Provisions | 0.37 Cr | — | — | — | — |
| Payables | 9.30 Cr | 32310.00 | 0.05 Cr | 6830.00 | — |
| Accounts Payable | 9.30 Cr | 30040.00 | 0.05 Cr | 0.00 | — |
| Total Assets | 27.21 Cr | 7.36 Cr | 7.26 Cr | 7.25 Cr | — |
| Total Non Current Assets | 0.27 Cr | 3.24 Cr | 3.01 Cr | 2.62 Cr | — |
| Non Current Deferred Taxes Assets | 0.04 Cr | 0.05 Cr | 0.06 Cr | 0.07 Cr | — |
| Investmentin Financial Assets | 0.04 Cr | 3.06 Cr | 2.78 Cr | 0.59 Cr | — |
| Available For Sale Securities | 0.04 Cr | 3.02 Cr | 2.73 Cr | 0.55 Cr | — |
| Investment Properties | 0.00 | — | 0.00 | 1.74 Cr | 0.00 |
| Goodwill And Other Intangible Assets | 0.00 | 100.00 | 100.00 | 0.00 | — |
| Net PPE | 0.19 Cr | 0.12 Cr | 0.17 Cr | 0.23 Cr | — |
| Gross PPE | 0.19 Cr | 1.33 Cr | 1.35 Cr | 1.34 Cr | — |
| Construction In Progress | 0.00 | — | — | — | 0.00 |
| Other Properties | 0.19 Cr | — | 0.14 Cr | 0.14 Cr | 0.01 Cr |
| Current Assets | 26.93 Cr | 4.13 Cr | 4.24 Cr | 4.63 Cr | — |
| Other Current Assets | 0.25 Cr | — | -10.00 | -20.00 | — |
| Inventory | 0.84 Cr | 1.19 Cr | 0.82 Cr | 0.53 Cr | — |
| Accounts Receivable | 18.14 Cr | 0.01 Cr | 0.19 Cr | 0.10 Cr | — |
| Cash Cash Equivalents And Short Term Investments | 7.70 Cr | 2.62 Cr | 2.77 Cr | 2.60 Cr | — |
| Other Short Term Investments | 7.02 Cr | 2.50 Cr | 2.50 Cr | 0.40 Cr | — |
| Cash And Cash Equivalents | 0.68 Cr | 0.12 Cr | 0.27 Cr | 2.60 Cr | — |
| Fixed Assets Revaluation Reserve | — | 0.00 | 0.00 | 0.00 | — |
| Retained Earnings | — | -2.41 Cr | -2.43 Cr | -2.37 Cr | -2.74 Cr |
| Additional Paid In Capital | — | 1.22 Cr | 1.22 Cr | 1.22 Cr | 1.22 Cr |
| Total Tax Payable | — | 2270.00 | 8420.00 | 760.00 | 0.01 Cr |
| Non Current Prepaid Assets | — | 0.00 | 0.00 | 0.12 Cr | 0.20 Cr |
| Trading Securities | — | 0.04 Cr | 0.04 Cr | 0.04 Cr | 50000.00 |
| Other Intangible Assets | — | 100.00 | 100.00 | 0.01 Cr | 0.03 Cr |
| Accumulated Depreciation | — | -1.21 Cr | -1.17 Cr | -1.12 Cr | -1.28 Cr |
| Machinery Furniture Equipment | — | 1.19 Cr | 1.20 Cr | 1.15 Cr | 1.38 Cr |
| Buildings And Improvements | — | 0.14 Cr | 0.14 Cr | 0.05 Cr | 0.14 Cr |
| Properties | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Prepaid Assets | — | 8480.00 | 0.01 Cr | 28260.00 | 0.10 Cr |
| Other Inventories | — | 0.87 Cr | 0.39 Cr | 0.12 Cr | 0.39 Cr |
| Finished Goods | — | 0.32 Cr | 0.43 Cr | 0.41 Cr | 0.44 Cr |
| Other Receivables | — | 0.07 Cr | 0.23 Cr | 1.19 Cr | 2.84 Cr |
| Taxes Receivable | — | 0.24 Cr | 0.21 Cr | 0.20 Cr | — |
| Cash Financial | — | 0.12 Cr | 0.27 Cr | 0.10 Cr | 0.47 Cr |
| Land And Improvements | — | — | 0.00 | 0.00 | 0.00 |
| Cash Equivalents | — | — | 2.50 Cr | 2.50 Cr | 1.61 Cr |
| Minority Interest | — | — | — | 0.27 Cr | 0.50 Cr |
| Other Payable | — | — | — | 6070.00 | 10000.00 |
| Other Non Current Assets | — | — | — | 110.00 | 1.36 Cr |
| Raw Materials | — | — | — | 0.41 Cr | 0.10 Cr |
| Long Term Equity Investment | — | — | — | — | 0.28 Cr |
| Investmentsin Associatesat Cost | — | — | — | — | 0.28 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on NOVELIX PHARMACEUTICALS LIMITE
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.